Toggle navigation
- Valbiotis announces its roadmap for 2023: a pivotal year in the execution of its clinical, industrial and commercial strategy.
Voir le communiqué de presse
- METabolic EXplorer secures financing for deployment of its strategy.
Voir le communiqué de presse
- Valbiotis announces the signature of a research partnership in intestinal microbiota with the MEDIS Unit from the Clermont Auvergne University.
Voir le communiqué de presse
- e Icare Group commits to the 2022 Octobre Rose operation
Voir le communiqué de presse
- Consolidated sales for the third quarter of 2022: €54.8 million (IN FRENCH).
Voir le communiqué de presse
- Valbiotis will present significant preclinical results for its active substance TOTUM•448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
Voir le communiqué de presse
- Valbiotis accelerates its marketing strategy.
Voir le communiqué de presse
- INVERS and the cooperatives Limagrain, Oxyane and Eurea create INVERS AURA, the first agricultural insect production line (IN FRENCH).
Voir le communiqué de presse
- Signing of a partnership agreement between Limagrain and VetAgro Sup on 5 October at the Livestock Summit (IN FRENCH).
Voir le communiqué de presse
- Aptys Pharma participates to Meet-up Pharma, on October 8 in Clermont-Ferrand (IN FRENCH).
Voir le communiqué de presse
